Stockscreener 앱 받기
4.12
2.14%
-0.09
시간 외 거래:
4.12
전일 마감가:
$4.21
열려 있는:
$4.24
하루 거래량:
202.81K
Relative Volume:
0.68
시가총액:
$166.43M
수익:
-
순이익/손실:
$-59.52M
주가수익비율:
-0.9353
EPS:
-4.4049
순현금흐름:
$-51.87M
1주 성능:
+24.85%
1개월 성능:
-14.17%
6개월 성능:
+44.06%
1년 성능:
+91.63%
1일 변동 폭
$3.9704
$4.32
1주일 범위
$3.29
$4.32
52주 변동 폭
$1.91
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.12 | 170.06M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
Survey finds most Boulder residents satisfied with quality of life - BizWest
OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser
OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser
ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan
TradingKey - TradingKey
The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com
OnKure Therapeutics (OKUR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
OnKure Therapeutics war chest nears $200M following spring stock sale - BizWest
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target - TipRanks
Onkure Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
OnKure (Nasdaq: OKUR) lifts cash to $192.1 million after raise - Stock Titan
OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan
OnKure Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
OnKure Therapeutics Reports First Quarter 2026 Financial Results - marketscreener.com
[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan
Aclarion reports cash runway to ops into late 2027 - BizWest
What date does OnKure Therapeutics, Inc.'s (OKUR) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN
OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
What top holdings OnKure Therapeutics (OKUR)? (Smart Money Active) 2026-04-27Earnings Beat Stocks - Newser
OKUR (OnKure Therapeutics) reports narrower Q4 2025 loss than estimates, shares drop 2.04 percent in trading.Revenue Growth Rate - Newser
Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6% - MarketBeat
OnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54 - MSN
OnKure Therapeutics (NASDAQ: OKUR) registers 36.1M shares for resale - Stock Titan
[DEF 14A] OnKure Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
OnKure Therapeutics (OKUR) Stock Bollinger Bands (Risk Aversion) 2026-04-20Small Cap Breakout - Cổng thông tin điện tử tỉnh Lào Cai
OnKure Therapeutics (OKUR) Stock Opening VWAP (Spikes) 2026-04-18Stock Distribution - Cổng thông tin điện tử tỉnh Lào Cai
Should I buy OnKure Therapeutics, Inc. (OKUR) - Zacks Investment Research
Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Increases By 1,958.6% - MarketBeat
Revenue Check: Whats the profit margin of OnKure Therapeutics Inc2026 Volume Leaders & Growth-Oriented Investment Plans - baoquankhu1.vn
Growth Recap: Is Vistra Corp gaining market shareQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Access Industries (OKUR) discloses 19.99% OnKure stake and board right - Stock Titan
StepStone affiliates report 2.66M shares in OnKure (NASDAQ: OKUR) - Stock Titan
RA Capital group reports 9.99% stake in OnKure (NASDAQ: OKUR) - Stock Titan
Trails Edge holds 6.0% of OnKure (NASDAQ: OKUR) after private placement - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Trading Recap: Whats the profit margin of OnKure Therapeutics Inc2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
Onkure Therapeutics Inc (OKUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):